Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Analysis of survival by tumor response.

Anderson JR, Cain KC, Gelber RD.

J Clin Oncol. 1983 Nov;1(11):710-9.

PMID:
6668489
2.

Multiple myeloma resistant to melphalan: treatment with doxorubicin, cyclophosphamide, carmustine (BCNU), and prednisone.

Kyle RA, Pajak TF, Henderson ES, Nawabi IU, Brunner K, Henry PH, McIntyre OR, Holland JF.

Cancer Treat Rep. 1982 Mar;66(3):451-6.

PMID:
7060034
3.
4.
5.

Plasma cell myeloma. An interpretive review.

Bergsagel DE.

Cancer. 1972 Dec;30(6):1588-94. Review. No abstract available.

PMID:
4565818
6.

A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.

Forbes C, Shirran L, Bagnall AM, Duffy S, ter Riet G.

Health Technol Assess. 2001;5(28):1-110. Review.

7.

(18)F-FDG PET-guided salvage neoadjuvant radiochemotherapy of adenocarcinoma of the esophagogastric junction: the MUNICON II trial.

zum Büschenfelde CM, Herrmann K, Schuster T, Geinitz H, Langer R, Becker K, Ott K, Ebert M, Zimmermann F, Friess H, Schwaiger M, Peschel C, Lordick F, Krause BJ.

J Nucl Med. 2011 Aug;52(8):1189-96. doi: 10.2967/jnumed.110.085803. Epub 2011 Jul 15.

8.

Mutiple myeloma resistant to melphalan (NSC-8806) treated with cyclophosphamide (NSC-26271), prednisone (NSC-10023), and chloroquine (NSC-187208).

Kyle RA, Seligman BR, Wallace HJ Jr, Silver RT, Glidewell O, Holland JF.

Cancer Chemother Rep. 1975 May-Jun;59(3):557-62.

PMID:
1203882
9.

Impact of response to treatment on survival in multiple myeloma: results in a series of 243 patients.

Bladé J, López-Guillermo A, Bosch F, Cervantes F, Reverter JC, Montserrat E, Rozman C.

Br J Haematol. 1994 Sep;88(1):117-21.

PMID:
7803233
10.

In vivo determination of the fractional kill of human tumor cells by chemotherapeutic agents.

Berenbaum MC.

Cancer Chemother Rep. 1972 Oct;56(5):563-71. No abstract available.

PMID:
4652587
11.

Influence of age of host on the chemotherapy of murine myeloma LCP-1.

Teller MN, Bowie M, Mountain IM.

J Gerontol. 1974 Jul;29(4):360-5. No abstract available.

PMID:
4833754
12.

M-2 protocol for melphalan-resistant and relapsing multiple myeloma.

Cavo M, Galieni P, Tassi C, Gobbi M, Tura S.

Eur J Haematol. 1988 Feb;40(2):168-73.

PMID:
3345830
13.

Chemotherapy of multiple myeloma.

Durie BG.

Baillieres Clin Haematol. 1991 Jan;4(1):181-95. Review. No abstract available.

PMID:
2039858
14.

High-dose chemotherapy in multiple myeloma.

Goldschmidt H, Hegenbart U, Wallmeier M, Moos M, Haas R.

Leukemia. 1997 Dec;11 Suppl 5:S27-31. Review.

PMID:
9436935
15.

[Comparative efficacy of chemotherapy in myeloma and cancer patients with relatively long survival].

Iavorkovskiĭ LI, Soloveĭ DIa, Rastrigin VL, Riauzova LIu.

Probl Gematol Pereliv Krovi. 1982 Mar;27(3):11-3. Russian. No abstract available.

PMID:
7088915
16.

Multi-drug combination therapy with vincristine-melphalan-cyclophosphamide-prednisolone was more effective than cyclophosphamide-prednisolone in stage III myeloma. The Nagoya Myeloma Cooperative Study Group.

Shimizu K, Kamiya O, Hamajima N, Mizuno H, Kobayashi M, Hirabayashi N, Takeyama H, Kato R, Kawashima K, Nitta M, et al.

Jpn J Cancer Res. 1990 Dec;81(12):1320-7.

PMID:
2126002
17.

[Combination chemotherapy of multiple myeloma--BCNU.cyclophosphamide.procarbazine.prednisolone and MCNU.cyclophosphamide.procarbazine.prednisolone therapy].

Uzuka Y, Saito Y, Takahashi H, Komatsu M, Ito T.

Gan To Kagaku Ryoho. 1989 Jun;16(6):2269-73. Japanese.

PMID:
2735769
18.

Primary failure of bortezomib in newly diagnosed multiple myeloma--understanding the magnitude, predictors, and significance.

Cohen YC, Joffe E, Benyamini N, Dimopoulos MA, Terpos E, Trestman S, Held-Kuznetsov V, Avivi I, Kastritis E.

Leuk Lymphoma. 2016;57(6):1382-8. doi: 10.3109/10428194.2015.1121258. Epub 2016 Jan 4.

PMID:
26727104
19.

Thalidomide in patients with advanced multiple myeloma: a study of 83 patients--report of the Intergroupe Francophone du Myélome (IFM).

Yakoub-Agha I, Attal M, Dumontet C, Delannoy V, Moreau P, Berthou C, Lamy T, Grosbois B, Dauriac C, Dorvaux V, Bay JO, Monconduit M, Harousseau JL, Duguet C, Duhamel A, Facon T.

Hematol J. 2002;3(4):185-92.

PMID:
12189564
20.

Treatment of multiple myeloma.

Woodruff R.

Cancer Treat Rev. 1981 Dec;8(4):225-70. Review. No abstract available.

PMID:
7039824

Supplemental Content

Support Center